Clinical Trial Update: Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B [Phase 2]

View source ↗

Summary

Phase 2 trial update on combination therapy REP 2139-Ca with Pegasys for chronic hepatitis B completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Pegasys (pegylated interferon alfa-2a)
• REP 2139-Ca (REP 2139-Ca)

Snippet

Sponsor: Replicor Inc. | Conditions: Hepatitis B, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2019-05-08